Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 176

1.

Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer.

Pérol M, Chouaid C, Pérol D, Barlési F, Gervais R, Westeel V, Crequit J, Léna H, Vergnenègre A, Zalcman G, Monnet I, Le Caer H, Fournel P, Falchero L, Poudenx M, Vaylet F, Ségura-Ferlay C, Devouassoux-Shisheboran M, Taron M, Milleron B.

J Clin Oncol. 2012 Oct 1;30(28):3516-24. Epub 2012 Sep 4.

PMID:
22949150
[PubMed - indexed for MEDLINE]
Free Article
2.

First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial.

Gridelli C, Ciardiello F, Gallo C, Feld R, Butts C, Gebbia V, Maione P, Morgillo F, Genestreti G, Favaretto A, Leighl N, Wierzbicki R, Cinieri S, Alam Y, Siena S, Tortora G, Felletti R, Riccardi F, Mancuso G, Rossi A, Cantile F, Tsao MS, Saieg M, da Cunha Santos G, Piccirillo MC, Di Maio M, Morabito A, Perrone F.

J Clin Oncol. 2012 Aug 20;30(24):3002-11. doi: 10.1200/JCO.2011.41.2056. Epub 2012 Jul 9.

PMID:
22778317
[PubMed - indexed for MEDLINE]
Free Article
3.

Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial.

Zhang L, Ma S, Song X, Han B, Cheng Y, Huang C, Yang S, Liu X, Liu Y, Lu S, Wang J, Zhang S, Zhou C, Zhang X, Hayashi N, Wang M; INFORM investigators.

Lancet Oncol. 2012 May;13(5):466-75. doi: 10.1016/S1470-2045(12)70117-1. Epub 2012 Apr 17.

PMID:
22512843
[PubMed - indexed for MEDLINE]
4.

Erlotinib and pemetrexed as maintenance therapy for advanced non-small-cell lung cancer: a systematic review and indirect comparison.

Qi WX, Tang LN, He AN, Shen Z, Lin F, Yao Y.

Curr Med Res Opin. 2012 Apr;28(4):643-50. doi: 10.1185/03007995.2012.675880. Epub 2012 Mar 29. Review.

PMID:
22414178
[PubMed - indexed for MEDLINE]
5.

First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.

Han JY, Park K, Kim SW, Lee DH, Kim HY, Kim HT, Ahn MJ, Yun T, Ahn JS, Suh C, Lee JS, Yoon SJ, Han JH, Lee JW, Jo SJ, Lee JS.

J Clin Oncol. 2012 Apr 1;30(10):1122-8. doi: 10.1200/JCO.2011.36.8456. Epub 2012 Feb 27.

PMID:
22370314
[PubMed - indexed for MEDLINE]
Free Article
6.

Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective.

Thongprasert S, Tinmanee S, Permsuwan U.

Asia Pac J Clin Oncol. 2012 Mar;8(1):53-61. doi: 10.1111/j.1743-7563.2012.01528.x.

PMID:
22369444
[PubMed - indexed for MEDLINE]
7.

Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer.

Vergnenègre A, Ray JA, Chouaid C, Grossi F, Bischoff HG, Heigener DF, Walzer S.

Clinicoecon Outcomes Res. 2012;4:31-7. doi: 10.2147/CEOR.S25923. Epub 2012 Jan 26.

PMID:
22347803
[PubMed]
Free PMC Article
8.

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.

Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann AH, Visseren-Grul C, Gridelli C.

Lancet Oncol. 2012 Mar;13(3):247-55. doi: 10.1016/S1470-2045(12)70063-3. Epub 2012 Feb 16.

PMID:
22341744
[PubMed - indexed for MEDLINE]
9.

Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study.

Belani CP, Brodowicz T, Ciuleanu TE, Krzakowski M, Yang SH, Franke F, Cucevic B, Madhavan J, Santoro A, Ramlau R, Liepa AM, Visseren-Grul C, Peterson P, John WJ, Zielinski CC.

Lancet Oncol. 2012 Mar;13(3):292-9. doi: 10.1016/S1470-2045(11)70339-4. Epub 2012 Feb 14.

PMID:
22336221
[PubMed - indexed for MEDLINE]
10.

Role of pemetrexed in advanced non-small-cell lung cancer: meta-analysis of randomized controlled trials, with histology subgroup analysis.

Al-Saleh K, Quinton C, Ellis PM.

Curr Oncol. 2012 Feb;19(1):e9-e15. doi: 10.3747/co.19.891.

PMID:
22328848
[PubMed]
Free PMC Article
11.

Non-platinum regimens of gemcitabine plus docetaxel versus platinum-based regimens in first-line treatment of advanced non-small cell lung cancer: a meta-analysis on 9 randomized controlled trials.

Yu Y, Xu X, Du Z, Shi M.

Cancer Chemother Pharmacol. 2012 May;69(5):1265-75. doi: 10.1007/s00280-012-1833-y. Review.

PMID:
22297708
[PubMed - indexed for MEDLINE]
12.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica.

Lancet Oncol. 2012 Mar;13(3):239-46. doi: 10.1016/S1470-2045(11)70393-X. Epub 2012 Jan 26.

PMID:
22285168
[PubMed - indexed for MEDLINE]
13.

Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.

Ciuleanu T, Stelmakh L, Cicenas S, Miliauskas S, Grigorescu AC, Hillenbach C, Johannsdottir HK, Klughammer B, Gonzalez EE.

Lancet Oncol. 2012 Mar;13(3):300-8. doi: 10.1016/S1470-2045(11)70385-0. Epub 2012 Jan 24.

PMID:
22277837
[PubMed - indexed for MEDLINE]
14.

Cost-effectiveness of maintenance pemetrexed in patients with advanced nonsquamous-cell lung cancer from the perspective of the Swiss health care system.

Matter-Walstra K, Joerger M, Kühnel U, Szucs T, Pestalozzi B, Schwenkglenks M.

Value Health. 2012 Jan;15(1):65-71. doi: 10.1016/j.jval.2011.08.1737. Epub 2011 Oct 22.

PMID:
22264973
[PubMed - indexed for MEDLINE]
15.

Effectiveness and safety of pemetrexed-based doublet versus pemetrexed alone as second-line treatment for advanced non-small-cell lung cancer: a systematic review and meta-analysis.

Qi WX, Tang LN, He AN, Shen Z, Yao Y.

J Cancer Res Clin Oncol. 2012 May;138(5):745-51. doi: 10.1007/s00432-012-1155-9. Epub 2012 Jan 19. Review.

PMID:
22258853
[PubMed - indexed for MEDLINE]
16.

Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB-IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST).

Boni C, Tiseo M, Boni L, Baldini E, Recchia F, Barone C, Grossi F, Germano D, Matano E, Marini G, Labianca R, Di Costanzo F, Bagnulo A, Pennucci C, Caroti C, Mencoboni M, Zanelli F, Prochilo T, Cafferata MA, Ardizzoni A; Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC).

Br J Cancer. 2012 Feb 14;106(4):658-65. doi: 10.1038/bjc.2011.606. Epub 2012 Jan 12.

PMID:
22240782
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

A meta-analysis of paclitaxel-based chemotherapies administered once every week compared with once every 3 weeks first-line treatment of advanced non-small-cell lung cancer.

Gao G, Chu H, Zhao L, Gui T, Xu Q, Shi J.

Lung Cancer. 2012 Jun;76(3):380-6. doi: 10.1016/j.lungcan.2011.12.001. Epub 2012 Jan 9.

PMID:
22226626
[PubMed - indexed for MEDLINE]
18.

Cost effectiveness of treatment with new agents in advanced non-small-cell lung cancer: a systematic review.

Bongers ML, Coupé VM, Jansma EP, Smit EF, Uyl-de Groot CA.

Pharmacoeconomics. 2012 Jan;30(1):17-34. doi: 10.2165/11595000-000000000-00000. Review.

PMID:
22201521
[PubMed - indexed for MEDLINE]
19.

Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta-analysis from six phase III randomized controlled trials.

Gao G, Ren S, Li A, Xu J, Xu Q, Su C, Guo J, Deng Q, Zhou C.

Int J Cancer. 2012 Sep 1;131(5):E822-9. doi: 10.1002/ijc.27396. Epub 2012 Jan 27.

PMID:
22161771
[PubMed - indexed for MEDLINE]
20.

A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer.

Nuijten MJ, de Castro Carpeño J, Chouaid C, Vergnenègre A, Grossi F, Bischoff H, Heigener D, Walzer S.

Lung Cancer. 2012 Jun;76(3):465-71. doi: 10.1016/j.lungcan.2011.11.005. Epub 2011 Dec 5.

PMID:
22153602
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk